Cargando…

Prognostic value of receptor tyrosine kinases in malignant melanoma patients: A systematic review and meta-analysis of immunohistochemistry

BACKGROUND: Substantial evidence suggests that receptor tyrosine kinases (RTKs) are overexpressed in tumors; however, few studies have focused on the prognostic value of RTKs in melanoma. OBJECTIVES: The objective of this study is to evaluate the association between overexpression of RTKs and surviv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lei, Xuan, Zhang, Yiming, Mao, Lianghao, Jiang, Pan, Huang, Yumeng, Gu, Jia, Tai, Ningzheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538722/ https://www.ncbi.nlm.nih.gov/pubmed/36212475 http://dx.doi.org/10.3389/fonc.2022.819051

Ejemplares similares

Expression and Prognostic Evaluation of the Receptor Tyrosine Kinase MET in Canine Malignant Melanoma
por: Koo, Karen, et al.
Publicado: (2023)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant Mesothelioma
por: Guo, Zhenying, et al.
Publicado: (2021)

Thymidine Kinase 1 Drives Skin Cutaneous Melanoma Malignant Progression and Metabolic Reprogramming
por: Zuo, Sipeng, et al.
Publicado: (2022)

Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
por: Abbas, Hussein A., et al.
Publicado: (2021)

Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value
por: Najem, Ahmad, et al.
Publicado: (2021)

Prognostic Value and Biological Function of Galectins in Malignant Glioma
por: Zhu, Hongtao, et al.
Publicado: (2022)

Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer
por: Zheng, Zongtai, et al.
Publicado: (2020)

Prognostic and Clinicopathological Value of Ki-67 in Melanoma: A Meta-Analysis
por: Liu, Qixin, et al.
Publicado: (2021)

Comprehensive Analysis of a Ferroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Landscape in Osteosarcoma
por: Zhang, Yiming, et al.
Publicado: (2022)

Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma
por: Zilenaite, Dovile, et al.
Publicado: (2020)

Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry
por: Placke, Jan-Malte, et al.
Publicado: (2021)

De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma
por: Ma, Si-Cong, et al.
Publicado: (2021)

Tyrosine kinases in nodal peripheral T-cell lymphomas
por: Piccaluga, Pier Paolo, et al.
Publicado: (2023)

Prognostic Value of the Platelet-to-Lymphocyte Ratio in Patients With Melanoma: A Meta-Analysis
por: Zhang, Feng, et al.
Publicado: (2020)

Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma
por: Dong, Xubin, et al.
Publicado: (2021)

Multiplexed Immunohistochemistry and Digital Pathology as the Foundation for Next-Generation Pathology in Melanoma: Methodological Comparison and Future Clinical Applications
por: Van Herck, Yannick, et al.
Publicado: (2021)

A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma
por: Shi, Binhao, et al.
Publicado: (2023)

Protein Tyrosine Kinase 7 Regulates EGFR/Akt Signaling Pathway and Correlates With Malignant Progression in Triple-Negative Breast Cancer
por: Cui, Nai-Peng, et al.
Publicado: (2021)

Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia
por: Hu, Chi-Hao, et al.
Publicado: (2023)

Prognostic and Predictive Value of BGN in Colon Cancer Outcomes and Response to Immunotherapy
por: He, Zi-Xuan, et al.
Publicado: (2022)

Prognostic value of spleen tyrosine kinase in human solid tumors
por: Ni, Beibei, et al.
Publicado: (2018)

Prognostic value of tumor markers in malignant melanoma
por: Treskova, Inka, et al.
Publicado: (2014)

Value of immunohistochemistry in the diagnosis of malignant cervical lymph nodes
por: de Natale Caly, Décio, et al.
Publicado: (2015)

Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors
por: Gachechiladze, Mariam, et al.
Publicado: (2020)

Immunohistochemistry and Bioinformatics Identify GPX8 as a Potential Prognostic Biomarker and Target in Human Gastric Cancer
por: Zhang, Xiaojie, et al.
Publicado: (2022)

Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma
por: Feng, Yiyi, et al.
Publicado: (2021)

Prognostic Value of Peripheral Inflammatory Markers in Preoperative Mucosal Melanoma: A Multicenter Retrospective Study
por: Wang, Yixi, et al.
Publicado: (2019)

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
por: Tian, Zhichao, et al.
Publicado: (2020)

Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers
por: Tao, Zhonghua, et al.
Publicado: (2021)

The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
por: Rozitis, Eric, et al.
Publicado: (2020)

The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis
por: Li, Baibei, et al.
Publicado: (2022)

Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry
por: Engqvist, Hanna, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies
por: Zhao, Yuming, et al.
Publicado: (2021)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
por: Hu, Chen-Yu, et al.
Publicado: (2019)

MYC Immunohistochemistry Predicts MYC Rearrangements by FISH
por: Nwanze, Julum, et al.
Publicado: (2017)

Review of Immunohistochemistry Biomarkers in Pancreatic Cancer Diagnosis
por: Luu, Tuan Trong
Publicado: (2021)

Malignant Evaluation and Clinical Prognostic Values of m6A RNA Methylation Regulators in Glioblastoma
por: Du, Jianyang, et al.
Publicado: (2020)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cepj4jfg46i4ab1h1nb2cls6ht